Inhibiting tumor cell plasticity by targeting the epigenome in breast cancer

Project description

Novel epigenetic targets in breast cancer

One of the hallmarks of cancer is heterogeneity, the presence of subpopulations of cells with distinct morphological, phenotypic and genotypic profiles. Although this affects the efficacy of anti-cancer therapeutics, the underlying aetiology is poorly defined. The EU-funded EPICAN project focuses on the phosphoinositide 3-kinase (PI3K) pathway, a signal transduction system implicated in many essential cell functions as well as in oncogenesis. The working hypothesis is that PI3K oncogenic mutations reactivate multipotency in mammary cells, leading to tumour plasticity and heterogeneity. Identification of epigenetic regulators that function downstream of the PI3K pathway has the potential to lead to new therapeutic targets.

Fields of science

• medical and health sciences › clinical medicine › oncology › breast cancer
• natural sciences › biological sciences › genetics › mutation
• natural sciences › biological sciences › genetics › epigenetics

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2018 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2018

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

UNIVERSITAT BASEL

Net EU contribution

€ 191 149,44

Address

Petersplatz 1
4051 Basel
Switzerland

Region

Schweiz/Suisse/Svizzera › Nordwestschweiz › Basel-Stadt

Activity type

Higher or Secondary Education Establishments

Links

Non-EU contribution

€ 0,00